Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
New advances in our understanding of the “unique” RNase L in host pathogen interaction and immune signaling

Elona Gusho a, Danika Baskar a,b, Shuvojit Banerjee a,*

* Address correspondence to this author.
E-mail addresses: banerjs2@ccf.org, banerjs2@gmail.com (S. Banerjee).
1. Introduction

Endoribonucleases are essential for diverse physiological processes, including control of gene expression by regulating RNA processing and turnover, cellular stress responses, antimicrobial defenses, and inflammation. They often operate through closely controlled mechanisms to maintain normal cellular homeostasis. Ribonuclease L (RNase L) is a classic example of a tightly regulated endoribonuclease as it is controlled by IFN-inducible oligo-adenylate synthetases (OASs) and double-stranded RNAs (dsRNAs) [reviewed in [1,2]]. RNase L (previously known as 2-5A dependent ribonuclease) is a metal ion-independent endoribonuclease (molecular weight of 83 KDa) that functions in the Type-I-III IFN-regulated 2′-5′-OAS-RNase L pathway [2].

The OAS-RNase L (Fig. 1) pathway, discovered in the mid-1970s [3–10], was one of the first IFN-dependent antiviral pathways to be characterized. OASs are IFN-I/-III-inducible genes that are expressed at very low basal levels in many cell types, except for immune cells such as macrophages [11–13]. Virus-infected cells induce the production of Type-I IFNs, which then activate JAK-STAT signaling [14], leading to the induction of hundreds of genes classified as members of the IFN-stimulated gene family, including the OASs [15]. OASs-3 (but not OASL) act as pathogen recognition receptors that sense dsRNAs and activate the synthesis of 5′-phosphorylated 2′-5′ linked oligoadenylates from ATP. The 2′-5′ linked oligoadenylates [with a chemical structure of p5′A(2p5′A)n, where x = 1–3; n > 2] are commonly referred to as 2-5A [5]. 2-5A acts as a second messenger and binds monomeric RNase L, and activates its dimer formation [16]. Naturally occurring 2-5A contains three phosphoryl groups in the 5′ end [5]; however, 2-5A monophosphorylated on the 5′ end has also been found to activate RNase L under in vitro conditions [16]. Active RNase L cleaves cellular and viral RNAs [17] within single-stranded regions, predominantly at the 3′-end of UN dinucleotides (preferentially after UU or UA), to produce RNA products that have a 5′-OH group and 2′,3′-cyclic phosphate at the 3′ end [18–20]. RNA degradation directly and indirectly activates subsequent events (Fig. 2), including the elimination of viral genomes, inhibition of cellular and viral protein synthesis [17]; and activation of several cellular signaling pathways, including those involved in autophagy.
apoptosis [23–25], senescence [26], IFN-β production [27–29], and NLRP3-inflammasome activation [30] as part of its antiviral mechanism.

In this review, we will first highlight recent discoveries on the ribonuclease function of RNase L, including its activation and targeting of certain RNAs; then comment on implications of several cellular events as potential targets for novel therapeutic intervention.

2. RNase L biochemistry and its activation

RNase L, first cloned in 1993 [31], is constitutively expressed in every human cell type in an inactive conformation. In mouse cells, its expression is slightly induced by IFN stimulation [32]. Human RNase L contains 741 amino acids and three domains: (i) the N-terminal ankyrin repeat domain (ARD), which contains one partial and eight complete ankyrin repeat domains; (ii) a protein kinase-like domain (PKL) or kinase homology domain that lacks the conserved DFG motif found in most protein kinases and contains a DFD sequence, similar to protein kinases Mnk1/2. So far, no kinase activity has been reported for PKL and hence RNase L is considered to be a pseudokinase. The PKL domain consists of a bi-lobal fold with a short N-terminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe); and (iii) Extending as a rigid protrusion from the PKL C-lobe is the C-terminal of the nuclease domain. This kinase homology domain and the kinase extension of the nuclease (KEN) domain have structural similarity with IRE1, a metal ion-independent endoribonuclease activated during the endoplasmic stress response. The homology suggests that RNase L and IRE1 may share similar catalytic mechanisms [33].

The precise mechanism of RNase L activity was elucidated by the determination of the crystal structure of full-length dimeric RNase L in a complex with 2-5A and an ATP analog. Early structural studies identified two different 2–5A binding sites (2 and 4 ANKD) in the ankyrin domain (ANKD) [34]. In contrast, the crystal structure of 2-5A bound to full-length RNase L provided evidence that 2-5A binds both the ANK-repeat domain and the N-lobe of the PKL domain to facilitate its dimerization [35,36]. ATP and ADP binding to the pseudokinase site leads to the formation of the single closed conformation, which is the activated form of RNase L. Detailed studies of ribonuclease activity and RNase L targets are highlighted in the following sections.
3. Cellular and viral inhibitors of OAS-RNase L

Several cellular and viral inhibitors of OAS-RNase L pathway have been identified (Table 1). These inhibitors act at different levels such as: sequestering dsRNA thus preventing or suppressing OAS activation, directly binding and inhibiting RNase L, and degrading 2-5A molecules hence inhibiting the dimerization and ribonuclease activity of RNase L. During viral infections, RNase L degrades both viral and cellular RNAs in single-stranded regions, including rRNA in intact ribosomes [37,38]. Many, perhaps most viruses, have evolved or acquired strategies that antagonize the OAS-RNase L pathway to evade antiviral innate immunity (Fig. 1).

Inhibitors of RNase L are encoded by widely different types of viruses, indicating that RNase L targets a variety of viruses. The influenza A virus (IAV) non-structural 1 protein (NS1) contains an N-terminal RNA-binding domain which binds to and sequesters dsRNA, the activator of OAS [39–41]. RNase L inhibits IAV (NS1-mutant) replication by cleaving viral genomic RNA in sites encoding PB2, PB1, and PA proteins critical for viral replication [42]. In a similar mechanism, the herpes simplex virus type 1 (HSV1) US11 gene product [43] and vaccinia virus (VacV) E3L protein binds dsRNA to inhibit the innate immune response [44–46]. Recently two separate studies [47,48] found that VacV encodes decapping enzymes D9 and D10 which are capable of degrading methylated mRNA cap structures, making them susceptible to the cellular 5′ exonuclease Xrn1. Infection with D9, D10 catalytic mutant viruses significantly increased dsRNA-induced activation of OAS and PKR, similar to Xrn1 mutation. In addition, protein 7 of transmissible gastroenteritis coronavirus (TGEV) binds to protein phosphatase 1 catalytical subunit, and it inhibits eIF2α dephosphorylation by protein kinase R (PKR) and rRNA degradation by RNase L [49]. Other viral proteins bind to monomeric RNase L to prevent dimerization. The L′ protein of Theiler's murine encephalomyelitis virus (TMEV, a picornavirus) binds to the ankyrin domain of murine RNase L and inhibits 2-5A binding and RNase L activation. Interestingly the L′ protein is species-specific and binds to murine but not to human RNase L [50]. A phylogenetically conserved highly structured RNA within the open reading frame of poliovirus and other group C enteroviruses also serves as a competitive inhibitor of RNase L. (cIRNA). cIRNA does not impair the 2-5A binding but instead acts as a competitive inhibitor of the RNASE domain, and the inhibitory function requires a putative E-motif and H-H kissing loop [51,52].

An increasing number of viruses have been identified to encode for 2′,5′-phosphodiesterases (PDEs) that directly degrade the 2-5A activator molecules [reviewed in [53]]. These 2′,5′-PDEs belong to

Table 1

| Target | Cellular | Viral |
|--------|----------|------|
| dsRNA  | –        | IAV NS1; VacV E3L, D9, D10; TGEV protein 7 |
| RNase L | ABCE1 | Poliovirus cIRNA; TMEV L′ |
| 2-5A   | AKA7, ENPP1, PDE12 | MHV n3; RVA VP3-CTD; MERS-CoV NS4b |

Fig. 2. Role of RNase L in antiviral innate immunity and cellular pathways.
the 2H-phosphoesterase superfamily of proteins, characterized by two conserved His-X-Thr/Ser motifs in their active site [54]. The non-structural 2 (ns2) protein of group 2a coronavirus mouse hepatitis virus (MHV), a member of the viral Lig-T family of 2H-phosphoesterases, was necessary for replication of A59 strain of MHV in livers of infected mice as well as liver pathogenesis [55]. ns2 degraded 2-5A in vitro. A catalytically mutant histidine virus A59-ns2H126R had significantly lower titers compared to wild type MHV in livers of infected mice as well as liver pathogenesis [55]. Although from evolutionarily non-related viruses, VP3 degraded 2-5A in similar manner as ns2 [54,57,58].

Although from evolutionarily non-related viruses, VP3 degraded 2-5A in similar manner as ns2 in vitro and in intact cells, whereas mutation of the two conserved histidines in the PDE catalytic site of VP3 prevented 2-5A degradation. Furthermore, the VP3 C-terminal domain restored the function of catalytically mutant ns2 when inserted into a non-essential gene ns4 in a chimeric MHV [57]. Another viral 2′,5′-PDE is the NS4b protein of Middle East respiratory syndrome coronavirus (MERS-CoV). Structurally homologous to MHV-ns2, nuclear protein NS4b also degrades 2-5A and was able to restore the function of a mutant ns2 in a chimeric MHV. Mutation of the NS4b PDE region activated RNase L, resulting in rRNA cleavage [59].

Several host PDEs can also degrade 2-5A (Fig. 1, Table 1). The A kinase anchoring protein 7 (AKAP7) is a cellular member of the 2H-phosphoesterase superfamily [54,60]. AKAP7 degraded 2-5A in vitro with rates similar to its viral homologues, ns2 of MHV and VP3 of RVA. The 2H central domain of the murine AKAP7 restored replication of ns2 mutant MHV chimeric virus whereas MHV chimeras with a histidine-to-arginine mutation in the His-X-Thr motif of AKAP7 central domain failed to replicate in bone marrow macrophages of B6 mice [61]. Due to structural homology, it was proposed that AKAP7 could be the evolutionary precursor of viral 2′,5′ PDE members [58,61]. In addition, phosphodiesterase 12 (PDE12) is a member of the exonuclease-endonuclease phosphatase family that localizes in mitochondria and regulates mRNA turnover by removing the polyA tails [62,63]. Despite its mitochondrial localization, several studies have shown PDE12 to be an antagonist of OAS-RNase L. It directly cleaves the phosphodiester bonds of 2-5A in vitro. Decreased expression of PDE12 in cells reduced viral titers of VacV [64], but for EMCV, in the absence of PDE12 expression, greater multiplicity of infection was required for a cytopathic effect comparable to wild type cells [65]. Furthermore, the plasma membrane ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was also shown to have a 2′-5′ nuclelease activity by degrading 2-5 in vitro [66]. ATP binding cassette E1 (ABCE1), also known as RNase L inhibitor (RLI), is another mammalian protein that inhibits the OAS-RNase L pathway. ABCE1 was reported to directly bind to RNase L, preventing 2-5A binding [67] and it is induced during viral infection by EMCV and HIV [68–70].

In summary, viruses and host cells encode a variety of proteins that inhibit the OAS-RNase L pathway. In contrast, as discussed below, 2-5A is the only known physiological activator of the pathway.

4. Activation of the OAS-RNase L pathway

Since the discovery of the OAS-RNase L pathway, a significant amount of research has been directed toward identifying its activators and inhibitors [reviewed in [53]]. As discussed above, several inhibitors, including viral proteins, viral RNA antagonists, and host proteins, have been identified within the last few decades, but little is known about potential activators of this pathway. So far, 2-5A is the only well-characterized and known physiological activator of RNase L. In addition, studies on some small molecule activators have been published, but their potency is much less than that of 2-5A, as sub-nanomolar concentrations of 2-5A lead to the activation of RNase L [71].

2-5A synthesis occurs when dsRNAs bind to and activate IFN-inducible oligoadenylate synthetases (OAS1-3). The human OASs include OAS1, 2, 3, and L, and additional isoforms due to alternative splicing. OASs 1–3 are encoded on chromosome 12q24.1 arm and possess 2′–5′ nucleotidyl transferase activity. Human OAS L is catalytically inactive and is encoded on chromosome 12q24.2 [reviewed in [72]]. Each OAS protein contains a core polymerase β (pol-β)-like nucleotidyl transference domain [73] that has structural similarity with polyA polymerase, CCA-adding enzyme, and cGAS [74]. However, only the OASs and cGAS are known to polymerize nucleotides in the 2′–5′ orientation. Although OAS and cGAS have structural similarity, they differ in their substrate recognition. cGAS recognizes cytosolic dsDNA (B-form) and catalyzes cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) [74], whereas OASs 1-3 are activated by dsRNA (A-form) [75] and catalyze the synthesis of 2-5A. On the other hand, human OAS L has a catalytically inactive OAS domain at the N-terminal and contains two ubiquitin-like domains in the C-terminus [76], which are not present in any of the other OAS proteins. Human OAS L was shown to promote antiviral activity by enhancing RIG-I activation [77].

Among the OASs, OAS1 contains one OAS domain (catalytically active), and OAS2 and OAS3 contain two and three OAS domains respectively, but only the C-terminal OAS domain is catalytically active [reviewed in [12,72,73]]. The OAS active site contains three aspartic acids, which coordinate with two Mg2+ ions required for enzyme activity. OAS3 has higher affinity for long dsRNA segments. Both the catalytic and non-catalytic domains of OAS3 are involved in dsRNA binding, but only the C-terminal domain is involved in 2-5A synthesis [73]. OAS1, 2 and 3 all synthesize 2-5A in vitro, but in intact cells, OAS3 synthesis of 2-5A predominates [11,73,78]. In a recent study we used individual OAS knockout human cell lines and identified OAS3 as the principle enzyme required for optimal RNase L activation and its antiviral mechanisms [11]. OAS1 and OAS2 knockout cells produced 2-5A in amounts comparable to the parental cells in response to dsRNA or virus infection, whereas OAS3 knockout cells were completely deficient in 2-5A synthesis and lacked significant RNase L activation [11]. These findings support prior studies in which OAS3 was shown to exert antiviral activity against Dengue virus in an RNase L-dependent manner [79], indicating that OAS3 synthesizes active 2-5A in sufficient amounts for RNase L activation. OAS1 and OAS2 probably have antiviral functions that support OAS3 activity, but they might possibly have additional or alternative functions as well. Reconstituted OAS1 protein was reported to inhibit EMCV replication in an RNase L-independent manner [80,81], indicating that this protein may have an alternative antiviral mechanism.

Besides dsRNA sensing and IFN signaling, very little information is available on possible relationships between other cellular pathways and OAS-RNase L activation. The nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a member of the NOD-like receptor family (NLR), interacts with OAS2 (P69) and leads to the enhanced activation of RNase L in the poly(rC)-poly(rC)-induced human monocytic leukemia cell line THP1 [82]. NOD2 was also shown to bind ssRNA and activate IFNβ [83].

5. RNase L cleavage

Ribosomal RNA cleavage is one of the hallmarks of RNase L activation [37,38]. RNase L cleaves cellular and viral RNAs within single-stranded regions after a UN dinucleotide (with a preference...
The method used exploits the RNAs (HCV, IAV, polio virus) were precisely mapped. RNAs (rRNA, snRNA such as U6 and U3) and also specific mapping RNAs, however. In a recent modified RNA sequencing study by adhesion.

miRNAs involved in the suppression of cell proliferation and transcripts, indicating that RNase L may mimic the effect of some miRNAs involved in the suppression of cell proliferation and adhesion.

None of these studies focused on RNase L cleavage sites on viral RNAs, however. In a recent modified RNA sequencing study by Cooper and colleagues [18,42], RNase L target sites in the cellular RNAs (rRNA, snRNA such as U6 and U3) and also specific mapping of the viral RNAs (HCV, IAV, polio virus) were precisely mapped. The method used exploits the 2-3' cyclic phosphate at the 3' end of the cleaved RNA (which is a characteristic of metal ion-independent RNases) and employs 2-3' cyclic phosphate cDNA synthesis with Illumina sequencing to map RNase L targets from either in vitro cleaved RNAs or RNAs from virus-infected cells.

Unlike many studies that actively exclude rRNAs from RNA sequencing experiments to enrich for mRNA and other RNA populations, these two studies intentionally retained rRNAs to precisely locate RNase L-target and RNase L non-target cleavage sites in rRNAs. This method specifically identified two prominent RNase L-dependent cleavage sites in 18S RNA UU\(^{541}\) and UU\(^{493}\) [18,42]. This method also uncovered other RNase L-dependent and - independent cleavage sites within the ribosomal RNAs, most of which were mapped in association with the single-stranded region at the ribosome surface. In addition, these methods allowed for the precise mapping of endoribonuclease cleavage sites in viral RNAs from IAV (ANS1) infected cells [18,42]. The influenza A virus has eight negative sense RNA (genome) segments (PB1, PB2, PA, HA, NA, NP, M and NS segments) encoding one or multiple viral proteins required for viral replication and pathogenesis. The endoribonuclease cleavages were prominent at discrete locations in PB2, PB1, PA, NP and M RNA segments, and RNase L knockdown reduced the amount of cleavage [42]. Large numbers of cleavage sites were detected within or adjacent to some areas of increased synonymous-site conservation. It was noted that RNase L-mediated cleavage was more prominent in the M positive-strand than in the other positive strand IAV RNAs, which has a uridine-rich 15-base sequence (\(\text{200AUUUAGGAAAUGUG}_G\))\(_{214}\). The cleavage sites in M RNA lay within the area of increased synonymous-site conservation, 50 bases downstream from the M4 splice donor sequence. Cleavage sites also occurred more frequently in the PA, PB1, and PB2 segments of the IAV genome (\(\text{--ve strand}\) than in other IAV genomic RNAs, suggesting that the viral nucleocapsid does not protect IAV RNAs from RNase L-mediated cleavage within the ribonucleoprotein complexes. Prominent cleavages were mapped within specific regions of IAV RNAs, including some areas of increased synonymous-site conservation such as the PB1-positive and -negative strands, NP-positive strands, and PA-negative strands. PB2 negative-strand RNA was cleaved in discrete regions without increased synonymous-site conservation. Compared to the other segments, the HA and NA segments have less synonymous-site conservation and therefore are less susceptible to RNase L-mediated cleavage. Because the viral packaging signals tend to be uridine-rich sequences within the areas of increased synonymous-site conservation [86,87] and on the basis of patterns of synonymous-site of conservation and RNase L target sites, it might be interesting to consider that the viral RNA packaging signals are potential targets of RNase L. Although the study by Cooper et al. precisely mapped RNase L cleavage sites in viral RNAs, for cellular RNAs only highly abundant cellular RNAs like 28SRNA, 18SRNA, and U6 RNA were precisely mapped.

6. Role of RNase L in autophagy

RNase L has been implicated in the induction of autophagy during viral infection [21,22]. Activation of autophagy conferred antiviral resistance during the early stages of EMCV infection but promoted viral replication during later phases. Both protein kinase R and c-jun kinase were shown to be involved in autophagy activation; however, the exact mechanism by which RNase L mediates autophagy is yet to be discovered [21]. It has been found that RNase L activation is essential for autophagy induction as a result of rRNA cleavage, which induces stress due to the RNA degradation. Ribosome turnover might be a potential cause of RNase L-mediated autophagy induction [22]. RNase L activation and RNase L cleavage products participate in crosstalk between autophagy and apoptosis, as RNase L cleavage products can activate the switch to apoptosis by caspase 3-dependent cleavage of Beclin 1 and hence may trigger cytochrome c release from mitochondria [88].

7. Role of RNase L in innate immunity

RNase L activation by dsRNA signaling or viral infection contributes to IFN-\(\beta\) production, indicating its important role in innate immunity. The ribonuclease function of RNase L is essential for its effect on IFN-\(\beta\) production [27-29]. RNase L-mediated cleavage products of both cellular and viral RNAs (less than 200 nt) are involved in the activation of pathogen recognition receptors such as RIG-I and MDA5 and hence activate downstream signaling cascades for IFN-\(\beta\) production [28,29]. These RNA species are designated as suppressor of virus RNA (svRNA) with a 2'-3'-cyclic phosphate [18] and 5'-hydroxyl (5'-OH) at the termini. The presence of the terminal phosphate on the cleaved RNA is essential for its recognition by RLRs (RIG-like receptors, RIG-I or MDA5) as calf intestinal phosphatase treatment diminished svRNA ability to produce IFN-\(\beta\) [28]. Moreover, mice deficient in RNase L had several-fold reduced levels of IFN-\(\beta\) induction after infection with RNA viruses (EMCV and Sendai virus) [29]. In MEF cells infected by HSV-2, a DNA virus, RNase L also induced production of IFN-\(\beta\) [89]. However, in mouse primary macrophages, RNase L negatively regulated IFN-\(\beta\) production after poly (I):poly (C) transfection or EMCV infection [90]. Compared to mouse embryonic fibroblasts (MEFs), the levels of the different OASs (1-3 and L1) in mouse primary macrophages is overall much higher, possibly explaining the observed elevation in RNase L activity. Increased RNase L activation eventually leads to cell death, which may explain the reduced IFN-\(\beta\) production in macrophages compared to MEFs [90].

8. Role of RNase L in inflammasome signaling

Recently we reported that RNase L is essential to NLRP3 inflammasome activation and IL-1\(\beta\) secretion during IAV infections in LPS-primed bone marrow-derived primary dendritic cells (BMDCs), human monocytes, THP1 cells, and thioglycollate-elicted primary peritoneal macrophages [30]. Inflammasomes are macromolecular complexes that induce inflammatory signaling upon activation by various signals, including pathogen-associated molecular patterns and danger-associated molecular
patterns. The canonical inflammasome activates caspase 1, which leads to the cleavage of pro-IL-1β and production of mature IL-1β. Cleaved IL-1β is then secreted through an unconventional pathway.

Recently, both NLR (NLRP3, NLRP6) and non-NLR (AIM2) inflammasomes have been shown to be involved in viral infection events, further activating downstream antiviral responses [reviewed in [91]]. NLRP3 is a multi-domain protein consisting of a NT-PYD (pyrin domain), a central NATCH domain, and C-terminal-leucine-rich repeat (LRR). Two signals are required for NLRP3 inflammasome activation: (i) a priming signal, which involves the transcriptional activation of NFκB target genes including NLRP3, caspase 1, and pro-IL-1β; and (ii) a second signal that is required for assembly of the macromolecular complex [92]. The NLRP3 inflammasome is activated during a wide range of RNA and DNA virus infections [reviewed in [91]]. We also found that RNase L activity had no effect on signal 1 (inflammasome priming) of LPS-primed mouse BMDCs, but did affect signal 2, activating the inflammasome.

Stable expression of wild-type human full-length RNase L, but not ribonuclease dead mutant (R667A), activates IL-1β and caspase 1 secretion in RNase L-deficient THP1 cells after virus infection or 2-5A transfection. Intracellular delivery of 2-5A activates IL-1β and caspase 1 secretion in culture supernatants of LPS-primed wild type mouse BMDCs but not in NLRP3, RNase L, and ASC-knockout BMDCs. RNase L-cleaved RNA products (both cellular total RNAs and IAV genomic RNAs) can activate IL-1β and caspase 1 in culture supernatants of LPS-primed BMDCs from wild-type mice and RNase L knockout mice but not in BMDCs of NLRP3 and ASC-knockout mice [30]. Earlier studies showed that RNase L increases IL-1β levels in bronchoalveolar lavage fluid and lung tissue after IAV infection [30]. We observed that RNase L activity had no effect on signal 1 (inflammasome priming) of LPS-primed mouse BMDCs, but did affect signal 2, activating the inflammasome.

The role of RNase L in cell migration and adhesion

As evidenced by earlier genetic studies, RNase L gene (RNASE L) was identified as a candidate for the hereditary prostate cancer 1 (HPC1) locus on human chromosome 1q24-25 through a combined positional cloning and candidate gene approach [100]. Since then, however, several studies have found a positive association [101-103] or no association [104-106] between hereditary prostate cancer and mutations, and variants in the RNASE L gene. One possible explanation includes the influence of environmental factors, such as microbial populations, that may regulate the activation of RNase L. In addition to the association with prostate cancer, mutations in the RNASE L gene have been implicated to an increased risk for other cancers including non-melanoma skin cancer [107], head and neck, uterine, cervix, breast [108], pancreatic [109], and hereditary non-polyposis colorectal cancers [110]. Recently, RNase L activity has been linked to several cellular processes that may contribute to the development of cancer, including apoptosis, autophagy, inflammation, and the suppression of a mobile genetic element (LINE1) [111]. An earlier study demonstrated that the prostate cancer cell lines PC3, LNCaP, and DU145 express higher levels of cellular RNA molecules that are capable of binding and activating OASs than do normal prostate epithelial cells [112]. These activators of OAS were identified to be mRNAs for Raf kinase inhibitor protein, poly(rC)-binding protein 2 (PCBP2), and human endogenous retrovirus envelope RNAs. This study also showed that PCBP2 mRNA levels were elevated during prostate cancer progression.

RNase L was reported to influence the activity of filamin A by affecting actin cytoskeleton formation, thereby inhibiting virus entry [113]. During viral infection, however, RNase L was released from the filamin A complex, enabling the activation of its nucleas-dependent antiviral function, which may further be involved in
processes such as cell adhesion and cell motility [113]. Recently, RNase L deficiency was found to enhance cell migration [85,114]. The inactivated nuclease mutant RNase L (R667A), which lacks catalytic activity, failed to suppress cell migration in PC3 cells, a highly metastatic prostate cancer cell line [114]. The expression of a nuclease dead mutant (W460) mouse RNase L only partially restored the inhibition of cell migration in comparison to wild-type mouse RNase L, expressed in RNase L deficient MEF cells. These findings suggest that both the nuclease-dependent and - independent properties of RNase L may be involved in regulating cell migration in MEFs. Transfection of PC3 cells with the RNase L activator 2-5A also suppressed cell migration, providing further evidence that RNase L catalytic activity is necessary for this process in prostate cancer cell lines [114].

In contrast, another report showed that RNase L deficiency decreases migration of bone marrow–derived macrophages [115]. This may possibly be due to cell type differences. In MEFs, both catalytic and non-catalytic domains of RNase L played a role in inhibiting cell migration, whereas in PC3 cells, only the nuclease domain showed a prominent effect. The exact mechanism by which IFN regulates RNase L to suppress cell migration remains to be determined. However, certain findings have begun to reveal features of this process. RNA cleavage products generated by RNase L were previously shown to activate innate immune signaling mechanisms through RIG-I (RLR), MDAS, and MAVS-like receptors. In contrast, siRNA mediated down regulation of RIG-I or MDAS or MAVS in PC3 cells did not affect cell migration. These results indicate that RNase L-mediated decay of miRNAs that encode for cell adhesion and migration proteins appears to be a key mechanism for RNase L-mediated inhibition of cell migration. RNase L-dependent mRNA decay selectively affects transcripts regulated by microRNAs (like mir17, mir-29, and mir-200 and other miRs) that negatively regulate mammalian cell adhesion and proliferation [85]. RNase L-mediated decay of miRNA targets may also potentially mimic the effects of some miRNAs that act as suppressors of proliferation and adhesion in mammalian cells. These studies extend the known biological roles and activities of RNase L to the inhibition of cell migration, adhesion, and proliferation, providing an explanation for the proposed link between mutations and variants in the RNASE L gene and increased cancer risk [101–

110].

11. Conclusion

RNase L is a unique IFN-regulated endoribonuclease that serves as an important mediator of antiviral innate immunity with possible roles in antibacterial defense and prostate cancer. The past few decades have witnessed remarkable advances in our understanding of RNase L and its biological activities. Prosing studies on RNase L structure and function are providing insight into its mode of action and biological role. Also several cellular pathways are implicated that are directly or indirectly required to protect the host from various infectious agents, allowing for increased control of host inflammation and related diseases, including cancer. Targeting optimum RNase L activation may provide a potential platform to develop broad-spectrum anti-microbial therapies for inflammatory diseases and cancer.

Acknowledgement

The author S.B would like to thank the organizers of Cytokine 2015 and International Cytokine and Interferon Society (ICIS) and the Millstein Family for giving the “Young Investigator Award” in Cytokine 2015, Bamberg, Germany. In addition, the authors would like to thank Dr. Robert Silverman and Dr. Cassandra Talercio at the Cleveland Clinic for reading and critically reviewing the manuscript. Finally, the authors would like to apologize to all scientists whose efforts could not be cited because of the space constraints.

References

[1] R.H. Silverman, Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response, J. Virol. 81 (2007) 12720–12725.
[2] R.H. Silverman, A scientific journey through the 2–5A/RNase L system, Cytokine Growth Factor Rev. 18 (2007) 381–388.
[3] A.G. Hovanessian, R.E. Brown, I.M. Kerr, Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells, Nature 268 (1977) 537–540.
[4] W.K. Roberts, M.J. Clemens, I.M. Kerr, Interferon-induced inhibition of protein synthesis in L-cell extracts: an ATP-dependent step in the activation of an inhibitor by double-stranded RNA, Proc. Natl. Acad. Sci. USA 73 (1976) 3136–3140.
[5] I.M. Kerr, R.E. Brown, PppA2p5′A2p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells, Proc. Natl. Acad. Sci. USA 75 (1978) 256–260.
[6] M.J. Clemens, B.R. Williams, Inhibition of cell-free protein synthesis by pppA2p5′A2p5′A: a novel oligonucleotide synthesized by interferon-treated L cell extracts, Cell 19 (1979) 557–572.
[7] L. Ratner, R.C. Wiegand, P.J. Farrell, G.C. Sen, B. Cabrer, P. Lengyel, Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseNT system into two macromolecular components: role of a small molecule in nucleic acid activation, Biochem. Biophys. Res. Commun. 81 (1978) 947–954.
[8] A. Schmidt, A. Zilberstein, L. Shulman, P. Federman, H. Beriselli, M. Revel, Interferon action: isolation of nuclease F, a translation inhibitor activated by interferon-induced (2′-5′)-oligoadenylate, FEBS Lett. 65 (1978) 257–264.
[9] C. Baglioni, M.A. Minks, P.A. Maroney, Interferon action mediated by activation of a nuclease by pppA2p5′A2p5′A, Nature 273 (1978) 684–687.
[10] A. Eppstein, C.E. Samuel, Mechanism of interferon action. Properties of an interferon-induced ribonucleolytic activity from mouse L929 cells, Virology 89 (1979) 240–251.
[11] Y. Li, S. Banerjee, Y. Wang, et al., Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses, Proc. Natl. Acad. Sci. USA 113 (8) (2016) 2241–2246.
[12] A.J. Sadler, B.R. Williams, Interferon-inducible antiviral effectors, Nat. Rev. Immunol. 8 (2008) 559–568.
[13] L. Zhao, L.D. Birdwell, A. Wu, et al., Cell-type-specific activation of the oligoadenylate synthase–RNase L pathway by a murine coronavirus, J. Virol. 87 (2013) 8408–8418.
[14] G.R. Stark, I.M. Kerr, B.R. Williams, R.H. Silverman, R.D. Schreiber, How cells respond to interferons, Annu. Rev. Biochem. 67 (1998) 227–264.
[15] S.D. Der, A. Zhou, B.R. Williams, R.H. Silverman, Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays, Proc. Natl. Acad. Sci. USA 95 (1998) 15623–15628.
[16] D.S. Dong, L. Xu, A. Zhou, et al., Intrinsic molecular activities of the interferon-induced 2–5A-dependent RNase, J. Biol. Chem. 269 (1994) 14153–14158.
[17] A. Chakraborti, B.K. Jha, R.H. Silverman, New insights into the role of RNase L in innate immunity, J. Cytokine Cytokine Res. 31 (2011) 49–57.
[18] D.A. Cooper, B.K. Jha, R.H. Silverman, J.R. Hesselberth, D.J. Barton, Ribonuclease L and metal-ion-dependent endoribonuclease cleavage sites in host and viral RNAs, Nat. Acids Res. 42 (2014) 5202–5216.
[19] D.H. Wreschner, J.W. McCauley, J.J. Skehel, I.M. Kerr, Interferon action: sequence specificity of the ppp(A2p5′A)n-dependent ribonuclease, Nature 289 (1981) 414–417.
[20] G. Lloyd-Smith, E. Statter, P. Lengyel, Interferon action: RNA cleavage pattern of a 2′-5′ oligoadenylate-dependent endonuclease, Science 212 (1981) 1029–1032.
[21] M.A. Siddiqui, K. Malathri, RNase L induces autophagy via c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase signaling pathways, J. Biol. Chem. 287 (2012) 43651–43664.
[22] A. Chakraborti, P.K. Ghosh, S. Banerjee, C. Goughan, R.H. Silverman, RNase L triggers autophagy in response to viral infections, J. Virol. 86 (2012) 11311–11321.
[23] A. Zhou, J. Paramaje, T.L. Brown, et al., Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L, EMBO J. 16 (1997) 6355–6363.
[24] M. Diaz-Guerra, C. Rivas, M. Esteban, Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells, Virology 236 (1997) 354–363.
[25] J.C. Castelli, R.A. Hassel, K.A. Wood, et al., A study of the interferon antiviral mechanism: apoptosis activation by the 2–5A system, J. Exp. Med. 186 (1997) 967–972.
[26] J.B. Andersen, X.L. Li, C.S. Judge, et al., Role of 2–5A-dependent RNase L in senescence and longevity, Oncogene 26 (2007) 3081–3088.
[27] P. Luthra, D. Sun, R.H. Silverman, B. He, Activation of IFN-β expression by a viral mRNA through RNase L and MDAS, Proc. Natl. Acad. Sci. USA 108 (2011) 2118–2123.
J.M. Thornborough, B.K. Jha, B. Yount, et al., Middle East respiratory syndrome coronavirus N54b protein inhibits RNase L activation, MBio 7 (2) (2016) e01463–e01468.

M.C. Gold, F.D. Smith, J.D. Scott, D. Barford, AKAP18 contains a phosphoesterase domain that binds AMP, J. Mol. Biol. 375 (2008) 1329–1343.

E. Gusho, R. Zhang, B.K. Jha, et al., Murine AKAP7 has a 2'-5'-phosphodiesterase domain that can cleave an inactive murine RNase L nuc gene, MBio 5 (2014) e01312–e01314.

J. Rorbach, T.J. Nicholls, M. Minzuk, PDE12 removes mitochondrial RNA poly (A) tails and controls translation in human mitochondria, Nucl. Acids Res. 35 (2017) 7750–7763.

J.B. Poulsen, K. Andersen, K.H. Kjaer, A.L. Vestergaard, J. Justesen, P.M. Martensen, Characterization of human phosphodiesterase 12 and identification of a novel 2'-5'-oligoadenylate nuclease – the ectonucleotide pyrophosphatase/phosphodiesterase 1, Biochimie 94 (2012) 1098–1107.

C. Bical, C. Martinand, M. Silhol, B. Lebleu, C. Bisbal, RNase L pathway is induced during human immunodeficiency virus type 1 infection and down regulates the 2'-5'A RNase L pathway in human T cells, J. Virol. 73 (2009) 290–299.

C. Martinand, T. Salehzada, M. Silhol, B. Lebleu, C. Bisbal, The RNase L inhibitor (RLI) is induced by double-stranded RNA, J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 18 (1998) 1031–1038.

C. Martinand, T. Salehzada, M. Silhol, B. Lebleu, C. Bisbal, RNase L inhibitor (RLI) anti-sense construction: partial down regulation of the 2'-5'a RNase L pathway in encephalomyocarditis-virus-(EMCV)-infected cells, Eur. J. Biochem. 275 (2004) 248–255.

C.S. Thakur, B.K. Jha, B. Dong, et al., Small-molecule activators of RNase L with broad-spectrum antiviral activity, Proc. Natl. Acad. Sci. USA 104 (2007) 9585–9590.

H. Kristiansen, H.H. Gad, S. Eskildsen-Larsen, P. Despres, R. Hartmann, The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities, J. Interferon Cytokine Res. 31 (2011) 41–47.

J. Donovan, G. Whitney, S. Rath, A. Korennykh, Structural mechanism of sensing long dsRNA via a nonacytolic domain in human oligoadenylate synthetase 3, Proc. Natl. Acad. Sci. USA 112 (2015) 3949–3954.

F. Civril, T. Deimling, C.C. de Oliveira Mann, et al., Structural mechanism of cytosolic DNA sensing by cGAS, Nature 498 (2013) 332–337.

R. Hartmann, J. Justesen, S.N. Sarkar, G.C. Sen, V.C. Yee, Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced protein 2'-5'-oligoadenylate synthetase, Mol. Cell 12 (2003) 1173–1185.

J. Zhu, A. Ghosh, S.N. Sarkar, OASL – a new player in controlling antiviral innate immunity, Curr. Opin. Virol. 12 (2015) 15–19.

Z. Xu, Y. Zhang, A. Ghosh, Antiviral activity of human OAS protein is mediated by enhancing signaling of the RIG-I RNA sensor, Immunity 40 (2014) 936–948.

M.S. Ibsen, H.H. Gad, K. Thavachenel, T. Boesen, P. Despres, R. Hartmann, The 2'-5'oligoadenylate synthetase 3 enzyme potently synthesizes the 2'-5'-oligoadenylates required for RNase L activation, J. Virol. 88 (2014) 14222–14231.

R.J. Lin, H.P. Yu, B.L. Chang, W.C. Tang, C.L. Liao, Y.L. Lin, Distinct antiviral roles for human 2'-5'-oligoadenylate synthetase family members against dengue virus infection, J. Immunol. 183 (2009) 8035–8043.

H. Kristiansen, C.A. Scherer, M. McVean, et al., Extracellular 2'-5'-oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity, J. Virol. 84 (2010) 11898–11904.

K. Thavachenel, H.H. Gad, M.S. Ibsen, et al., Rapid uptake and inhibition of viral propagation by extracellular OAS1, J. Interferon Cytokine Res. 33 (2013) 342–356.

J.W. Dugan, A. Albor, L. David, et al., Nucleotide oligomerization domain-2 interacts with 2'-5'-oligoadenylate synthetase 2 and enhances RNaseL function in THP-1 cells, Mol. Immunol. 47 (2010) 312–316.

A. Sabah, T.H. Chang, R. Jaffar, M. McVean, Functional immune responses by Nod2, Nat. Immunol. 10 (2009) 1073–1080.

J.B. Andersen, K. Mazan-Mamczarz, M. Zhan, M. Gorospe, B.A. Hassel, Ribonuclease: a uniquely regulated mediator of interferon action, Cell 72 (1993) 953–961.

H. Kristiansen, C.A. Scherer, M. McVean, et al., Extracellular 2'-5'-oligoadenylate synthetase stimulates RNase L-independent antiviral activity, J. Virol. 84 (2010) 11898–11904.

K. Thavachenel, H.H. Gad, M.S. Ibsen, et al., Rapid uptake and inhibition of viral propagation by extracellular OAS1, J. Interferon Cytokine Res. 33 (2013) 342–356.
M.A. Siddiqui, S. Mukherjee, P. Manivannan, K. Malathi, RNase L cleavage products promote switch from autophagy to apoptosis by caspase-mediated cleavage of beclin-1, Int. J. Mol. Sci. 16 (2015) 17631–17636.

S.B. Rasmussen, S.B. Jensen, C. Nielsen, et al., Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production, J. Gen. Virol. 90 (2009) 74–78.

S. Banerjee, A. Chakrabarti, B.K. Jha, S.R. Weiss, R.H. Silverman, Cell-type-specific effects of RNase L on viral induction of beta interferon, MBio 5 (2014) e00856–00814.

L.Y. Chen, T. Ichinohe, Response of host inflammasomes to viral infection, Trends Microbiol. 23 (2015) 55–63.

L. Lamkanfi, V.M. Dixit, Mechanisms and functions of inflammasomes, Cell 157 (2014) 1013–1022.

L. Franchi, T. Egenbrord, R. Munoz-Planillo, et al., Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+ efflux, J. Immunol. 193 (2014) 4214–4222.

N. Subramaniam, K. Natarajan, M.R. Clatworthy, Z. Wang, R.N. Germain, The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation, Cell 153 (2013) 348–361.

H. Mitoma, S. Hanabuchi, T. Kim, et al., The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome, Immunity 39 (2013) 123–135.

Y. Liu, N. Lu, B. Yuan, et al., The interaction between the helicase DHX33 and IPS-1 as a novel pathway to sense double-stranded RNA and RNA viruses in myeloid dendritic cells, Cell. Mol. Immunol. 11 (2014) 49–57.

X.L. Li, H.J. Ezelle, T.J. Kang, et al., An essential role for the antiviral endoribonuclease, RNaseL, in antibacterial immunity, Proc. Natl. Acad. Sci USA 105 (2008) 20816–20821.

T.M. Long, A. Chakrabarti, H.J. Ezelle, et al., RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer, Inflamm. Bowel Dis. 19 (2013) 1295–1305.

T.M. Long, S. Nisa, M.S. Donnenberg, B.A. Hassel, Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function, Infect. Immun. 82 (2014) 2802–2814.

J. Carpent, N. Nupponen, S. Isaacs, et al., Germline mutations in the ribonuclease L gene in families showing linkage with HPC1, Nat. Genet. 30 (2002) 181–184.

G. Casey, P.J. Neville, S.J. Plummer, et al., RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases, Nat. Genet. 32 (2002) 581–583.